Advertisement
Screener

Korro Bio, Inc. (KRRO) Current Income Tax Expense (Benefit)

1.6 / 5 stars · 14/45 Roast Me

Korro Bio, Inc. Current Income Tax Expense (Benefit)

Korro Bio, Inc. (KRRO) reported Current Income Tax Expense (Benefit) of $637.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.

Financial Statements › Expense Statement › Income Tax

us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-12

  • Korro Bio, Inc. current income tax expense (benefit) for fiscal 2025 was $637.00K, a 351.77% increase from fiscal 2024.
  • Korro Bio, Inc. current income tax expense (benefit) for fiscal 2024 was $141.00K, a 422.22% increase from fiscal 2023.
  • Korro Bio, Inc. current income tax expense (benefit) for fiscal 2023 was $27.00K, a 170.00% increase from fiscal 2022.
  • Korro Bio, Inc. current income tax expense (benefit) for fiscal 2022 was $10.00K, a 33.33% decline from fiscal 2021.
Period endCurrent Income Tax Expense (Benefit) 12 monthCurrent Income Tax Expense (Benefit) 12 month as first filed
2025-12-31$637.00K
10-K · filed 2026-03-12
2024-12-31$141.00K
10-K · filed 2026-03-12
2023-12-31$27.00K
10-K · filed 2025-03-18
2022-12-31$10.00K
10-K · filed 2024-03-26
-$2.00K
10-K · filed 2023-03-10
2021-12-31$15.00K
10-K · filed 2023-03-10
2020-12-31$35.00K
10-K · filed 2022-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Atrium Therapeutics, Inc. (RNA)United States$0.140B
SPRUCE BIOSCIENCES, INC. (SPRB)United States$0.142B-2.89
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
Annexon, Inc. (ANNX)United States$0.147B-4.22
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
IMMUNIC, INC. (IMUX)United States$0.127B-1.88